Can Olanzapine and Clonazepam Cause Transaminitis?
Yes, both olanzapine and clonazepam can cause elevated liver transaminases (transaminitis), with olanzapine being a well-documented and relatively common cause, while clonazepam-induced hepatotoxicity is rare but reported.
Olanzapine and Hepatotoxicity
Olanzapine is significantly associated with liver enzyme elevations. In a 2026 multicenter real-world study of 487 hospitalized bipolar disorder patients, olanzapine-associated hepatotoxicity occurred in 24.2% of patients, with most cases (19.3%) being mild 1. The FDA label confirms that olanzapine is highly metabolized by the liver, with only 7% excreted unchanged in urine, making hepatic metabolism a critical pathway 2.
Key Risk Factors for Olanzapine-Induced Transaminitis:
- Higher daily dosage (OR: 1.070, significant independent risk factor) 1
- Elevated baseline gamma-glutamyl transferase (GGT) (OR: 1.022) 1
- Underlying liver disease - can have additive effects leading to accelerated transaminase elevations 3
- Obesity, geriatric or pediatric age, and concurrent hepatotoxic substances 4
Clinical Pattern:
- Injury patterns are predominantly mixed in mild-to-moderate cases and hepatocellular in severe cases 1
- Can present with asymptomatic transaminase elevations or progress to marked increases (ALT >1500 U/L reported) 5
- Onset typically occurs within days to weeks of initiation 5
Important Caveat:
Concomitant valproate use was paradoxically associated with reduced hepatotoxicity risk (OR: 0.553), suggesting potential protective effects in this specific context 1. This contradicts typical assumptions about polypharmacy and liver injury.
Clonazepam and Hepatotoxicity
Clonazepam-induced liver dysfunction is rare but documented. The FDA label notes that clonazepam undergoes hepatic metabolism, and metabolites are renally excreted, requiring caution in patients with hepatic impairment 6.
Evidence for Clonazepam-Induced Transaminitis:
A 2019 case report documented a 50-year-old man who developed liver dysfunction, severe hyperlipidemia, and hyperglycemic crisis 13 days after starting clonazepam 0.5 mg daily 7. Notably:
- Patient had pre-existing mild liver dysfunction from alcohol use
- Liver function and lipid abnormalities resolved within 7 days of clonazepam discontinuation without other intervention
- This suggests clonazepam can aggravate existing liver dysfunction
High-Risk Scenario:
Patients with pre-existing hyperlipidemia and liver dysfunction are at particular risk when clonazepam is initiated 7.
Clinical Management Algorithm
Monitoring Strategy:
- Baseline liver function tests (ALT, AST, GGT, bilirubin) before initiating either medication
- Repeat LFTs at 2 weeks, 1 month, then every 3 months during olanzapine treatment, especially in first 6 months 1, 5
- For clonazepam: monitor LFTs if patient has pre-existing liver disease or develops symptoms 7
Action Thresholds:
- ALT/AST >3× ULN without symptoms: Reduce olanzapine dose and recheck in 1 week 4
- ALT/AST >5× ULN or >3× ULN with symptoms: Discontinue medication immediately 5, 4
- Rising transaminases despite dose reduction: Discontinue medication 4
Expected Recovery:
Most patients show rapid improvement after medication withdrawal, with normalization typically within 1-2 weeks 1, 5, 7. Conservative management with hepatoprotective agents may be considered, though spontaneous resolution is common 1.
Critical Pitfall to Avoid
Do not attribute all transaminitis to concurrent conditions when olanzapine is on board. In one case, transaminitis was initially attributed solely to acute hepatitis C infection, but ALT rapidly decreased only after holding olanzapine, demonstrating its contributory role 3. When multiple potential causes exist, a trial of stopping the suspected medication provides diagnostic clarity.